Lipogems Canine Scientific Data Collection From
•
0 likes•185 views
This form can be used by Lipogems accredited vets to submit scientific data to a central database for research and development
Report
Share
Report
Share
Download to read offline
Recommended
Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes
OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa
ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efficacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs significantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneficial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue ...
Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue ...Lipogems Equine & Lipogems Canine
The itinerary and keynote speaker list for the May 2018 Lipogems Regenerative Medicine SeminarLipogems regenerative medicine seminar by lipocast biotech uk itinerary for s...
Lipogems regenerative medicine seminar by lipocast biotech uk itinerary for s...Lipogems Equine & Lipogems Canine
This is a short presentation about the translation of Lipogems concept and technology for veterinary use in equine and canine application. This presentation also includes a series of download links to published papers, abstracts and study models from the human application. Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With...
Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With...Lipogems Equine & Lipogems Canine
Recommended
Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue in Dogs with Spontaneous Osteoarthritis: Safety, Feasibility, and Clinical Outcomes
OFFER ZEIRA,a SIMONE SCACCIA,a LETIZIA PETTINARI,a ERICA GHEZZI,a NIMROD ASIAG,a LAURA MARTINELLI,a DANIELE ZAHIRPOUR,a MARIA P. DUMAS,a MARTIN KONAR,a DAVIDE M. LUPI,a LAURENCE FIETTE,b LUISA PASCUCCI,c LEONARDO LEONARDI,c ALISTAIR CLIFF,d GIULIO ALESSANDRI,e AUGUSTO PESSINA,f DANIELE SPAZIANTE,g MARINA ARALLAa
ABSTRACT Similar to the disease affecting humans, osteoarthritis (OA) is a painful musculoskeletal condition affecting 20% of the adult canine population. Several solutions have been proposed, but the results achieved to date are far from being satisfactory. New approaches, such as intra-articular delivery of cells (including mesenchymal stromal cells), have been proposed. Among the many sources, the adipose tissue is considered very promising. We evaluated the safety, feasibility, and efficacy of a single intra-articular injection of autologous and micro-fragmented adipose tissue (MFAT) in 130 dogs with spontaneous OA. MFAT was obtained using a minimally invasive technique in a closed system and injected in the intra- and/or peri-articular space. Clinical outcomes were determined using orthopedic examination and owners’ scores for up to 6 months. In 78% of the dogs, improvement in the orthopedic score was registered 1 month after treatment and continued gradually up to 6 months when 88% of the dogs improved, 11% did not change, and 1% worsened compared with baseline. Considering the owners’ scores at 6 months, 92% of the dogs significantly improved, 6% improved only slightly, and 2% worsened compared with baseline. No local or systemic major adverse effects were recorded. The results of this study suggest that MFAT injection in dogs with OA is safe, feasible, and beneficial. The procedure is time sparing and cost-effective. Post injection cytological investigation, together with the clinical evidence, suggests a long-term pain control role of this treatment. The spontaneous OA dog model has a key role in developing successful treatments for translational medicine. STEM CELLS TRANSLATIONAL MEDICINE 2018;00:1–10Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue ...
Intra-Articular Administration of Autologous Micro-Fragmented Adipose Tissue ...Lipogems Equine & Lipogems Canine
The itinerary and keynote speaker list for the May 2018 Lipogems Regenerative Medicine SeminarLipogems regenerative medicine seminar by lipocast biotech uk itinerary for s...
Lipogems regenerative medicine seminar by lipocast biotech uk itinerary for s...Lipogems Equine & Lipogems Canine
This is a short presentation about the translation of Lipogems concept and technology for veterinary use in equine and canine application. This presentation also includes a series of download links to published papers, abstracts and study models from the human application. Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With...
Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 - With...Lipogems Equine & Lipogems Canine
This file is a step by step guide of how to conduct a Lipogems Canine procedure with a list of disposables required and do's and don'ts as well as aftercare details.Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1
Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1Lipogems Equine & Lipogems Canine
A step by step guide for the use of Lipogems Equine kits with a list of disposables required and do's and don'ts.Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...
Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...Lipogems Equine & Lipogems Canine
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis
Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7,
A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017
Results
The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results.The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...Lipogems Equine & Lipogems Canine
Mammalian MSC from Selected Species: Features and Applications
Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†*
Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications.Mammalian MSC from Selected Species: Features and Applications Christiane Ude...
Mammalian MSC from Selected Species: Features and Applications Christiane Ude...Lipogems Equine & Lipogems Canine
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development
Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2
Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting
Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes.Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...Lipogems Equine & Lipogems Canine
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1
Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population.Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...Lipogems Equine & Lipogems Canine
This presentation is for qualified registered small animal veterinary surgeons who are interested in using Lipogems Canine. The presentation outlines the science behind the concept, an outline of the procedure, some case study data and links for further reading. Please be aware this presentation contains videos and therefore the file is very large and may take some time to download. For a quick download please request the link for the quick PDF download. Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With...
Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With...Lipogems Equine & Lipogems Canine
This presentation is a short preview of the translated technology. It outlines the science behind the concept and explains some of the misconceptions of tissue graft technology. The preview also contains extensive links to online published research papers and retrospective studies.Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2
Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 Lipogems Equine & Lipogems Canine
A presentation of the science behind Lipogems and its application for equine use, this presentation also includes an outline of the procedure and case study data. This presentation is only for the use of qualified registered veterinary surgeons.Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...Lipogems Equine & Lipogems Canine
An extended preview covering the translated science from huma to equine application with a review of the procedure and case study data. This preview is only intended for qualified registered veterinary surgeons. For quick download - videos have been de-activated in PDF format. For active videos please download the PP Presentation version.Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...Lipogems Equine & Lipogems Canine
Veterinary Record including Lipogems Canine launch in their products and services pages explaining the application of Lipogems for canine orthopaedic conditions and details of the first UK referral centre.Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...
Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...Lipogems Equine & Lipogems Canine
Holly Kernot from Vet Times writes about the launch of Lipogems Canine in the UK with Lead Lipogems Canine Veterinary Surgeon Alistair Cliff from Crown Vets Referrals. The feature outlines how Lipogems Canine can be used in a range of conditions that affect dogs.Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...
Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...Lipogems Equine & Lipogems Canine
More Related Content
More from Lipogems Equine & Lipogems Canine
This file is a step by step guide of how to conduct a Lipogems Canine procedure with a list of disposables required and do's and don'ts as well as aftercare details.Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1
Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1Lipogems Equine & Lipogems Canine
A step by step guide for the use of Lipogems Equine kits with a list of disposables required and do's and don'ts.Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...
Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...Lipogems Equine & Lipogems Canine
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteogly can Synthesis in Patients with Knee Osteoarthritis
Damir Hudetz 1,2,3,*, Igor Borić 1,4,5, Eduard Rod 1, Željko Jeleč 1, Andrej Radić 1, Trpimir Vrdoljak 1,2, Andrea Skelin 1,6, Gordan Lauc 6,7,
A prospective, non-randomized, interventional, single-center, open-label clinical trial was conducted from January 2016 to April 2017
Results
The results of our study indicate that the use of autologous and micro-fragmented adipose tissue in patients with knee OA (measured by dGEMRIC MRI) increased glycosaminoglycan (GAG) content in hyaline cartilage, which is in line with observed VAS and clinical results.The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...Lipogems Equine & Lipogems Canine
Mammalian MSC from Selected Species: Features and Applications
Christiane Uder, Sandra Br€uckner, Sandra Winkler, Hans-Michael Tautenhahn,†‡ Bruno Christ†*
Mesenchymal stromal/stem cells (MSC) are promising candidates for cellular therapy of different diseases in humans and in animals. Following the guidelines of the International Society for Cell Therapy, human MSC may be identified by expression of a specific panel of cell surface markers (CD1051, CD731, CD901, CD34-, CD14-, or CD11b-, CD79- or CD19-, HLA-DR-). In addition, multiple differentiation potential into at least the osteogenic, adipogenic, and chondrogenic lineage is a main criterion for MSC definition. Human MSC and MSC of a variety of mammals isolated from different tissues meet these criteria. In addition to the abovementioned, they express many more cell surface markers. Yet, these are not uniquely expressed by MSC. The gross phenotypic appearance like marker expression and differentiation potential is similar albeit not identical for MSC from different tissues and species. Similarly, MSC may feature different biological characteristics depending on the tissue source and the isolation and culture procedures. Their versatile biological qualities comprising immunomodulatory, anti-inflammatory, and proregenerative capacities rely largely on the migratory and secretory capabilities of MSC. They are attracted to sites of tissue lesion and secrete factors to promote self-repair of the injured tissue. This is a big perspective for clinical MSC applications in both veterinary and human medicine. Phase I/II clinical trials have been initiated to assess safety and feasibility of MSC therapies in acute and chronic disease settings. Yet, since the mode of MSC action in a specific disease environment is still unknown at large, it is mandatory to unravel the response of MSC from a given source onto a specific disease environment in suitable animal models prior to clinical applications.Mammalian MSC from Selected Species: Features and Applications Christiane Ude...
Mammalian MSC from Selected Species: Features and Applications Christiane Ude...Lipogems Equine & Lipogems Canine
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development
Carlo Tremolada1 & Valeria Colombo1 & Carlo Ventura2
Abstract Inthepastfewyears,interestinadiposetissueasan ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered Bmini-drugstores.^ MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinicalresults.Moreover, these techniquesare hampered by complex regulatory issues. Therefore, an innovative technique (Lipogems®; Lipogems International SpA, Milan, Italy) was developed to obtain microfragmented adipose tissue with an intact stromal vascular niche and MSCs with a high regenerative capacity. The Lipogems® technology, patented in 2010 and clinically available since 2013, is an easyto-use system designed to harvest, process, and inject refined fat tissue and is characterized by optimal handling ability and a great regenerative potential based on adipose-derived MSCs. In this novel technology, the adipose tissue is washed, emulsified, and rinsed and adipose cluster dimensions gradually are reduced to about 0.3 to 0.8 mm. In the resulting
Lipogems® product, pericytes are retained within an intact stromal vascular niche and are ready to interact with the recipient tissue after transplantation, thereby becoming MSCs and starting the regenerative process. Lipogems® has been used in more than 7000 patients worldwide in aesthetic medicineandsurgery,aswellasinorthopedicandgeneralsurgery, with remarkable and promising results and seemingly no drawbacks. Now, several clinical trials are under way to supporttheinitialencouragingoutcomes.Lipogems®technology is emerging as a valid intraoperative system to obtain an optimal final product that may be used immediately for regenerative purposes.Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...Lipogems Equine & Lipogems Canine
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells Valentina Ceserani1†, Anna Ferri1*†, Angiola Berenzi2, Anna Benetti2, Emilio Ciusani3, Luisa Pascucci4, Cinzia Bazzucchi4, Valentina Coccè5, Arianna Bonomi5, Augusto Pessina5, Erica Ghezzi6, Offer Zeira6, Piero Ceccarelli4, Silvia Versari7, Carlo Tremolada7 and Giulio Alessandri1
Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population.Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...Lipogems Equine & Lipogems Canine
This presentation is for qualified registered small animal veterinary surgeons who are interested in using Lipogems Canine. The presentation outlines the science behind the concept, an outline of the procedure, some case study data and links for further reading. Please be aware this presentation contains videos and therefore the file is very large and may take some time to download. For a quick download please request the link for the quick PDF download. Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With...
Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With...Lipogems Equine & Lipogems Canine
This presentation is a short preview of the translated technology. It outlines the science behind the concept and explains some of the misconceptions of tissue graft technology. The preview also contains extensive links to online published research papers and retrospective studies.Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2
Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2 Lipogems Equine & Lipogems Canine
A presentation of the science behind Lipogems and its application for equine use, this presentation also includes an outline of the procedure and case study data. This presentation is only for the use of qualified registered veterinary surgeons.Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...Lipogems Equine & Lipogems Canine
An extended preview covering the translated science from huma to equine application with a review of the procedure and case study data. This preview is only intended for qualified registered veterinary surgeons. For quick download - videos have been de-activated in PDF format. For active videos please download the PP Presentation version.Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...Lipogems Equine & Lipogems Canine
Veterinary Record including Lipogems Canine launch in their products and services pages explaining the application of Lipogems for canine orthopaedic conditions and details of the first UK referral centre.Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...
Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...Lipogems Equine & Lipogems Canine
Holly Kernot from Vet Times writes about the launch of Lipogems Canine in the UK with Lead Lipogems Canine Veterinary Surgeon Alistair Cliff from Crown Vets Referrals. The feature outlines how Lipogems Canine can be used in a range of conditions that affect dogs.Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...
Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...Lipogems Equine & Lipogems Canine
More from Lipogems Equine & Lipogems Canine (16)
Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1
Lipocast Biotech UK Lipogems Canine Standard Operating Procedure v1
Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...
Lipocast Biotech UK Lipogems Equine Standard Operating Procedure 007 - withou...
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...
The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tis...
Minimal Criteria for Defining MSC's. The ISCT Position Statement
Minimal Criteria for Defining MSC's. The ISCT Position Statement
Mammalian MSC from Selected Species: Features and Applications Christiane Ude...
Mammalian MSC from Selected Species: Features and Applications Christiane Ude...
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...
Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Tec...
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...
Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue an...
IFATS Presentation by Dr offer Zeira - 2016 20.11.16
IFATS Presentation by Dr offer Zeira - 2016 20.11.16
Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With...
Lipocast Biotech UK Lipogems Canine Veterinary Presentation 2017 v.1.3 - With...
Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2
Lipocast Biotech UK Lipogems Equine and Canine Presentation 2017 v.1.2
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Lipocast Biotech UK Lipogems Equine Veterinary Presentation 2017 v.1.4 - With...
Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...
Veterinary Record - Lipogems story - Regenerative therapy for canine joint co...
Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...
Vet Times 2017 Lipogems Canine Feature - Novel regeneration therapy available...
Recently uploaded
Recently uploaded (20)
Creating and Analyzing Definitive Screening Designs
Creating and Analyzing Definitive Screening Designs
❤Jammu Kashmir Call Girls 8617697112 Personal Whatsapp Number 💦✅.
❤Jammu Kashmir Call Girls 8617697112 Personal Whatsapp Number 💦✅.
Recombination DNA Technology (Nucleic Acid Hybridization )
Recombination DNA Technology (Nucleic Acid Hybridization )
Recombinant DNA technology (Immunological screening)
Recombinant DNA technology (Immunological screening)
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Chemical Tests; flame test, positive and negative ions test Edexcel Internati...
Chemical Tests; flame test, positive and negative ions test Edexcel Internati...
Stunning ➥8448380779▻ Call Girls In Panchshil Enclave Delhi NCR
Stunning ➥8448380779▻ Call Girls In Panchshil Enclave Delhi NCR
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Pulmonary drug delivery system M.pharm -2nd sem P'ceutics
Pulmonary drug delivery system M.pharm -2nd sem P'ceutics
Hire 💕 9907093804 Hooghly Call Girls Service Call Girls Agency
Hire 💕 9907093804 Hooghly Call Girls Service Call Girls Agency
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
TEST BANK For Radiologic Science for Technologists, 12th Edition by Stewart C...
Lipogems Canine Scientific Data Collection From
- 1. KITE SERIAL NUMBER _ _ _ -_ _ _ _ _ _ -_ _ DATE OF PROCEDURE _ _ -_ _ -_ _ _ _ AMOUNT OF PRE-CANISTER ASPIRATED MATERIAL COLLECTED __________ ml AMOUNT OF LIPOASPIRATE POST- PROCESS __________ ml AMOUNT OF LIPOASPIRATE INJECTED IN EACH ARTICULATION _________ ml ARTICULATIONS TREATED (please list all details) ________________________________________________________________ ________________________________________________________________ TOTAL LIPOASPIRATE USED __________ ml CASE CLINICAL NOTES (PLEASE CONTINUE ON A SEPARATE SHEET IF NEEDED AND SUPPLY ANY LAB REPORTS OF JOINT FLUID/ XRAYS OR SCANS WHERE APPLICABLE) FOLLOW UP OBSERVATIONS (PLEASE CONTINUE ON A SEPARATE SHEET IF NEEDED) VET & PRACTICE DETAILS: ___________________________________________________________________ ___________________________________ SIGNED:_________________________ Please tick this box if the owner has given NOT given permission for public use of this case. Please tick this box if you are NOT happy for this data to be disclosed to other researchers. Lipogems Canine Data Collection From